INVESTMENT OFFERING

Available as a Portfolio or Individually

SAB Capital is pleased to present a prime investment opportunity: the fee-simple acquisition of three single-tenant R&D/Lab facilities operated and guaranteed by Velocity Clinical Research. These properties, available individually or as a portfolio, offer stable, long-term cash flow with minimal landlord responsibilities.

The offering includes three strategically located facilities:

Savannah, GA – 6,880 SF on 0.14 acres

Binghamton, NY – 9,984 SF on 1.48 acres

Norfolk, NE – 11,008 SF on 2.48 acres

Each property is ideally positioned along key regional thoroughfares, ensuring accessibility and high traffic.

The Tenant, Velocity Clinical Research, is a global leader in clinical trials, providing innovative solutions for pharmaceutical and biotech companies. With a network of 90+ sites and 220+ investigators across the U.S. and Europe, Velocity is one of the most rapidly growing research organizations in the industry. The company ranked #543 on the 2023 Inc. 5000 list, demonstrating its exceptional growth trajectory.

This portfolio represents a rare opportunity to acquire stabilized, net-leased assets in a high-demand industry with strong fundamentals. Investors seeking secure, long-term cash flow with rental growth will find this an exceptional addition to their portfolio.

• PASSIVE LEASES | The net lease structure on the three properties provides for passive income with limited responsibilities. Investors can rely on predictable cash flow with little management required
• NO EARLY TERMINATION OR KICK-OUT CLAUSE |The three properties have no early termination or kick-out clauses during the initial lease term or option periods, ensuring investors a secure and stable return
• LEADING OPERATOR | Velocity Clinical Research is a global leader in the clinical research industry, offering innovative solutions for pharmaceutical and biotechnology companies. As the world’s leading organization of fully integrated clinical research sites, Velocity boasts an impressive network of over 90 sites and more than 220 investigators across the United States and Europe
• GROWING INDUSTRY | The global clinical trials market was valued at $83.75 billion in 2024 and is projected to grow to $149.58 billion by 2034. This growth is driven by increasing pharmaceutical R&D spending and demand for new drug development
• ANNUAL RENT GROWTH | The three leases feature annual rent escalations of 2%, ensuring steady rental income growth over the lease term. This built-in rent growth further enhances the investment’s return profile over time